Related Experiment Video
Updated: May 29, 2026
14:45
Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein
Published on: July 29, 2022
Parkinson's disease and α-synuclein expression
Michael J Devine1, Katrina Gwinn, Andrew Singleton
1Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London, UK. m.devine@ion.ucl.ac.uk
Movement Disorders : Official Journal of the Movement Disorder Society
|September 3, 2011
Summary
Genetic variations in the alpha-synuclein (α-synuclein) gene significantly impact Parkinson's disease. Locus multiplications and mutations highlight its critical role in disease development and offer therapeutic targets.
Area of Science:
- Neurogenetics
- Molecular Neurology
- Parkinson's Disease Research
Background:
- Genetic studies have transformed Parkinson's disease (PD) understanding.
- Alpha-synuclein (α-synuclein) is the first identified gene linked to PD and a key component of Lewy bodies.
- Variations in the α-synuclein locus are a major genetic risk factor for sporadic and familial Parkinson's disease.
Purpose of the Study:
- To review the clinical impact of α-synuclein locus multiplications in Parkinson's disease.
- To explore the implications of these genetic alterations for PD pathogenesis.
- To discuss potential disease-modifying therapeutic strategies for Parkinson's disease.
Main Methods:
- Review of genetic studies on Parkinson's disease.
- Analysis of clinical data related to α-synuclein gene variations.
- Discussion of molecular mechanisms and therapeutic approaches.
Main Results:
- Alpha-synuclein (α-synuclein) gene variations, including locus multiplications, are strongly associated with Parkinson's disease.
- Altered α-synuclein expression levels can lead to significant clinical phenotypes.
- These findings underscore the central role of α-synuclein in PD pathogenesis.
Conclusions:
- Alpha-synuclein (α-synuclein) is a critical determinant of Parkinson's disease risk and progression.
- Understanding the impact of α-synuclein gene multiplications provides insights into disease mechanisms.
- Targeting α-synuclein offers promising avenues for developing novel, disease-modifying therapies for Parkinson's disease.
More Related Videos
Related Concept Videos
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:37Neural Regulation
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...